The Manufacturers Life Insurance Company Acquires 10,264 Shares of Haleon plc (NYSE:HLN)

The Manufacturers Life Insurance Company boosted its holdings in Haleon plc (NYSE:HLN) by 0.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,799,005 shares of the company’s stock after acquiring an additional 10,264 shares during the period. The Manufacturers Life Insurance Company’s holdings in Haleon were worth $17,163,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in HLN. Wellington Management Group LLP increased its position in Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after buying an additional 6,175,835 shares during the period. Raymond James Financial Inc. bought a new position in Haleon during the fourth quarter worth about $42,193,000. FMR LLC raised its stake in Haleon by 3.7% in the 4th quarter. FMR LLC now owns 108,827,814 shares of the company’s stock worth $1,038,217,000 after purchasing an additional 3,909,545 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Haleon in the 4th quarter valued at about $39,628,000. Finally, JPMorgan Chase & Co. grew its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

NYSE:HLN opened at $10.68 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $48.19 billion, a PE ratio of 31.41, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon plc has a twelve month low of $8.12 and a twelve month high of $10.85. The stock’s 50-day simple moving average is $10.16 and its 200 day simple moving average is $9.81.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, analysts anticipate that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s dividend payout ratio is presently 58.97%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Finally, Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.